Literature DB >> 35983282

Quantification of Cannabis in Infused Consumer Products and Their Residues on Skin.

Rosalynn Quiñones1, Sara Moreno1,2, Amanda L Smythers3, Carrie Sullins1, Haley Pijor1,2, Glenna Brown2, Ashley Trouten4, Lauren L Richards-Waugh2, Aladin Siddig5.   

Abstract

Cannabis consumer products are a $4.6 billion industry in the U.S. that is projected to exceed $14 billion by 2025. Despite an absence of U.S. Food and Drug Administration (FDA) regulation or clinical data, thousands of nutraceuticals, topical consumer products, and beauty products claim benefits of hemp or cannabidiol. However, a lack of required quality control measures prevents consumers from knowing the true concentration or purities of cannabis-labeled products. Thirteen over-the-counter consumer products were examined for the presence of cannabidiol (CBD), cannabinol (CBN), Δ9-tetrahydrocannabinol (THC), cannabidiolic acid (CBDA), and Δ9-tetrahydrocannabinolic acid A (THCA). Additionally, the efficacy of topical applications was investigated using a porcine skin model, in which particle size and zeta potential relate to skin permeability. Skin permeation was correlated to particle size and relative stability in skin-like conditions but not directly related to the CBD content, suggesting that topical products can be designed to enhance overall skin permeation. Of the products analyzed, all products have some traceable amount of cannabinoids, while seven products had multiple cannabinoids with quantifiable amounts. Overall, the need for further regulation is clear, as most products have apparent distinctions between their true and labeled contents.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35983282      PMCID: PMC9380210          DOI: 10.1021/acsptsci.2c00077

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  35 in total

1.  Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology.

Authors: 
Journal:  J Anal Toxicol       Date:  2013-09       Impact factor: 3.367

2.  Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.

Authors:  Ryan Vandrey; Jeffrey C Raber; Mark E Raber; Brad Douglass; Cameron Miller; Marcel O Bonn-Miller
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

Review 3.  An Overview of Products and Bias in Research.

Authors:  David Gloss
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

4.  Benefits, toxicity and current market of cannabidiol in edibles.

Authors:  Gonzalo Astray; Juan C Mejuto; Jianbo Xiao; Jesus Simal-Gandara
Journal:  Crit Rev Food Sci Nutr       Date:  2022-01-06       Impact factor: 11.176

5.  Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis.

Authors:  Stefania Petrosino; Roberta Verde; Massimo Vaia; Marco Allarà; Teresa Iuvone; Vincenzo Di Marzo
Journal:  J Pharmacol Exp Ther       Date:  2018-04-09       Impact factor: 4.030

6.  Impact of semi-solid formulations on skin penetration of iron oxide nanoparticles.

Authors:  Umberto M Musazzi; Benedetta Santini; Francesca Selmin; Valentina Marini; Fabio Corsi; Raffaele Allevi; Anna M Ferretti; Davide Prosperi; Francesco Cilurzo; Miriam Colombo; Paola Minghetti
Journal:  J Nanobiotechnology       Date:  2017-02-17       Impact factor: 10.435

7.  Preferential Accumulation of Phospholipid-PEG and Cholesterol-PEG Decorated Gold Nanorods into Human Skin Layers and Their Photothermal-Based Antibacterial Activity.

Authors:  Nouf N Mahmoud; Ala A Alhusban; Jamila Isabilla Ali; Amal G Al-Bakri; Rania Hamed; Enam A Khalil
Journal:  Sci Rep       Date:  2019-04-08       Impact factor: 4.379

Review 8.  Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders.

Authors:  Sudhir M Baswan; Allison E Klosner; Kelly Glynn; Arun Rajgopal; Kausar Malik; Sunghan Yim; Nathan Stern
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-12-08

9.  A mixed methods analysis of cannabis use routines for chronic pain management.

Authors:  Kevin F Boehnke; Laura Yakas; J Ryan Scott; Melissa DeJonckheere; Evangelos Litinas; Suzanne Sisley; Daniel J Clauw; David A Williams; Jenna McAfee
Journal:  J Cannabis Res       Date:  2022-01-11

10.  A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans.

Authors:  Gerhard Nahler; Franjo Grotenhermen; Antonio Waldo Zuardi; José A S Crippa
Journal:  Cannabis Cannabinoid Res       Date:  2017-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.